Triastek Initiates Phase 1 Trial for Octreotide Acetate Tablets (T25) Bioavailability
Triastek is conducting Phase 1 trial to evaluate the bioavailability of T25 compared to Mycapssa and the food effect on pharmacokinetics.
Asset / Drug
Drug and asset intelligence for Triastek with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.